Achilles Therapeutics plc
NASDAQ:ACHL
1.04 (USD) • At close November 7, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Achilles Therapeutics plc |
Symbool | ACHL |
Munteenheid | USD |
Prijs | 1.045 |
Beurswaarde | 42,936,857 |
Dividendpercentage | 0% |
52-weken bereik | 0.63 - 1.76 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Iraj Ali |
Website | https://www.achillestx.com |
An error occurred while fetching data.
Over Achilles Therapeutics plc
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)